A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 µg)...

Update Il y a 5 ans
Reference: EUCTR2004-000025-29

A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 µg) delivered via a multiple dose inhaler and 1 dose of QAB149 (400 µg) delivered via a single dose inhaler in patients with chronic obstructive pulmonary disease (COPD)

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the bronchodilatory efficacy of QAB149 delivered via the MDDPI in patients with COPD


Inclusion criteria

  • Moderate to Severe Chronic Obstructive Pulmonary
  • Disease